Skip to main navigation

Top Navigation

About Us
- Our Company
- Contact Us
Our Pipeline
- Pipeline
  - ZN-c5
  - ZN-c3
  - ZN-d5
  - ZN-e4
- Clinical Trials
Our Approach
- Integrated Discovery Engine
- Supporting Publications
Investors & Media
Careers

Investors/Media

Press Releases

Press Releases

Year

May 20, 2020

Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics

May 15, 2020

Zentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Update

Apr 30, 2020

Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies

Apr 07, 2020

Zentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 02, 2020

Zentalis Pharmaceuticals Announces Pricing of Initial Public Offering

Jan 09, 2020

Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors

Investors/Media

Investor Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
- SEC Filings
Corporate Governance
Investor Resources

Investor Contact

Thomas Hoffmann
Solebury Trout
1.646.378.2931
thoffmann@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
1.646.378.2967
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

Privacy Policy
Terms of Use
Site Map

Copyright © 2020 Zentalis Pharmaceuticals. All Rights Reserved.